This work is licensed under the Creative Commons Attribution 4.0 International License.
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129:837–47.ChughSSHavmoellerRNarayananKSinghDRienstraMBenjaminEJWorldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study20141298374710.1161/CIRCULATIONAHA.113.005119415130224345399Search in Google Scholar
Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6:213–20.Zoni-BerissoMLercariFCarazzaTDomenicucciSEpidemiology of atrial fibrillation: European perspective201462132010.2147/CLEP.S47385406495224966695Search in Google Scholar
Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider K. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J. 2013; 166:442–8.KirchhofPBreithardtGCammAJCrijnsHJKuckKHVardasPWegscheiderKImproving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial2013166442810.1016/j.ahj.2013.05.01524016492Search in Google Scholar
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–51.ConnollySJEzekowitzMDYusufSEikelboomJOldgrenJParekhADabigatran versus warfarin in patients with atrial fibrillation200936111395110.1056/NEJMoa090556119717844Search in Google Scholar
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–91.PatelMRMahaffeyKWGargJPanGSingerDEHackeWRivaroxaban versus warfarin in nonvalvular atrial fibrillation20113658839110.1056/NEJMoa100963821830957Search in Google Scholar
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–92.GrangerCBAlexanderJHMcMurrayJJLopesRDHylekEMHannaMApixaban versus warfarin in patients with atrial fibrillation20113659819210.1056/NEJMoa110703921870978Search in Google Scholar
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093–104.GiuglianoRPRuffCTBraunwaldEMurphySAWiviottSDHalperinJLEdoxaban versus warfarin in patients with atrial fibrillation2013369209310410.1056/NEJMoa131090724251359Search in Google Scholar
Kim HM, Choi E-K, Park CS, Cha M-J, Lee S-Y, Kwon J-M, Oh S. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PLoS One. 2019; 14:e0211766. doi: 10.1371/journal.pone.0211766KimHMChoiE-KParkCSChaM-JLeeS-YKwonJ-MOhSEffectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation201914e021176610.1371/journal.pone.0211766640524430845196Open DOISearch in Google Scholar
Jung H, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. Chest. 2019; 155:354–63.JungHYangP-SJangEYuHTKimT-HUhmJ-SEffectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study20191553546310.1016/j.chest.2018.11.00930472021Search in Google Scholar
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69:236–9.RosendaalFRCannegieterSCvan der MeerFJBriëtEA method to determine the optimal intensity of oral anticoagulant therapy199369236910.1055/s-0038-1651587Search in Google Scholar
Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3:692–4.SchulmanSKearonCSubcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisDefinition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients20053692410.1111/j.1538-7836.2005.01204.x15842354Search in Google Scholar
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015; 12:e1001885. doi: 10.1371/journal.pmed.1001885BenchimolEISmeethLGuttmannAHarronKMoherDPetersenIRECORD Working CommitteeThe REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement201512e100188510.1371/journal.pmed.1001885459521826440803Open DOISearch in Google Scholar
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4:e296. doi: 10.1371/journal.pmed.0040296von ElmEAltmanDGEggerMPocockSJGøtzschePCVandenbrouckeJPSTROBE InitiativeThe Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies20074e29610.1371/journal.pmed.0040296202049517941714Open DOISearch in Google Scholar
Chan Y-H, See L-C, Tu H-T, Yeh Y-H, Chang S-H, Wu L-S, et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018; 7:e008150. doi: 10.1161/JAHA.117.008150ChanY-HSeeL-CTuH-TYehY-HChangS-HWuL-SEfficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation20187e00815010.1161/JAHA.117.008150601544229622587Open DOISearch in Google Scholar
Balcı KG, Balcı MM, Canpolat U, Şen F, Akboğa MK, Süleymanoğlu M, et al. Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. Anatol J Cardiol. 2016; 16:474–81.BalcıKGBalcıMMCanpolatUŞenFAkboğaMKSüleymanoğluMComparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation20161647481Search in Google Scholar
Rosner B. Fundamentals of biostatistics. 5th ed. Duxbery, MA: Thomson Learning; 2000.RosnerB5th ed.Duxbery, MAThomson Learning2000Search in Google Scholar
Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. Singapore: John Wiley & Sons; 2003.FleissJLLevinBPaikMC3rd ed.SingaporeJohn Wiley & Sons200310.1002/0471445428Search in Google Scholar
Ngamjarus C, Chongsuvivatwong V, McNeil E. n4Studies: sample size calculation for an epidemiological study on a smart device. Siriraj Med J. 2016; 68:160–70.NgamjarusCChongsuvivatwongVMcNeilEn4Studies: sample size calculation for an epidemiological study on a smart device20166816070Search in Google Scholar
Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. PLoS One. 2016; 11:e0164076. doi: 10.1371/journal.pone.0164076HaasSTen CateHAccettaGAngchaisuksiriPBassandJPCammAJQuality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry201611e016407610.1371/journal.pone.0164076508502027792741Open DOISearch in Google Scholar